Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2017 /
Nivolumab vs ipilimumab for high risk melanoma patients

8th - 12th Sep 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.09.17
Views: 644

Dr Jeffrey Weber - Perlmutter Cancer Center, New York, USA

Dr Weber presents in a press conferene at the ESMO 2017 Congress in Madrid the data from a large, randomised, phase III trial in which patients with stage IIIb/c/IV melanoma, identified as high risk individuals, were treated with either nivolumab or ipilimumab.

Dr Weber goes on to discuss the clinical and statistical benefit of nivolumab compared to ipilimumab with a 35% reduction in the risk of relapse and a 13% difference in 18 month relapse free survival rates, in favour of nivolumab. 

Dr Weber spoke with ecancer about the results here.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence